Skip to content

Early versus Late Allopurinol Initiation in an Acute Gout Attack: A Randomized Controlled Trial (ELAG)

Early versus Late Allopurinol Initiation in an Acute Gout Attack: A Randomized Controlled Trial (ELAG)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190223001
Enrollment
114
Registered
2019-02-23
Start date
2018-10-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute gout attack within 72 hours after onset Allopurinol&#44

Interventions

early allopurinol
starting allopurinol ar first day of study,Late allopurinol
starting allopurinol ar 14th day of study
Experimental Drug,No Intervention Drug
Early allopurinol,Late allopurinol

Sponsors

Navamindradhiraj University Research Fund
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients > 18 years old presented with an acute gout attack within 72 hours after onset, and crystal-proven gout by arthrocentesis founded MSU crystals and at least one of the following - Frequent attack ≥ 2/year, tophi by clinical exam or imaging study, CKD stage 2 or worse (Estimated Glomerular Filtration Rate 8 mg/dL during attack or comorbidities (at least one of following; hypertension, ischemic heart disease or congestive heart failure)

Exclusion criteria

Exclusion criteria: 1. CKD stage 5 (eGFR < 15) or on Renal replacement therapy 2. Prior use of uric lowering agents past month 3. History of adverse reactin to allopurinol or colchicine 3. Ongoing cancer treatment 4. concomitant use of azathioprine or cyclosporin 5. taking xanthine oxidase inhibitor or uricosuric agent withih 1 month 6. AST&#44; ALTand/or ALP level more than 2 times of upper normal limit 7. Neurologic deficit resulting in decreased pain sensatin around the involve joints 8. During intubation 9. Inability to return for examinations 10. presence of HLA&#45;B*5801 genes

Design outcomes

Primary

MeasureTime frame
time to complete resolution of acute gouty attack between early and late initiation of allopurinol 5 visit (day1&#44; day5&#45;9&#44; day 14&#44; day 19&#45;23 and day28) visual analog scale and physical examination

Secondary

MeasureTime frame
time to clinical resolution of the acute gout attack between early and late allopurinol group 5 visit (day1&#44; day5&#45;9&#44; day 14&#44; day 19&#45;23 and day28) visual analog scale ,relapse of arthritis 5 visit (day1&#44; day5&#45;9&#44; day 14&#44; day 19&#45;23 and day28) questionaire,Laboratory parameter (Serum uric acid&#44;eGFR&#44; ESR&#44; CRP) 3 visit (day1&#44; day 14&#44; and day28) blood test

Countries

Thailand

Contacts

Public ContactPanchalee Satpanich

Faculty of medicine Vajira Hospital

satpanichp@gmail.com0868999090

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026